Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray (<i>Potamotrygon</i> spp.) as a Drug Carrier in Glioblastoma Cancer Cells.

ABSTRACT: Glioblastoma is the most common and highly malignant brain tumor in adults. New targeted therapeutic approaches are imperative. EGFRvIII has appealing therapeutic targets using monoclonal antibodies. Thus, endeavors toward developing new mAbs therapies for GBM capable of targeting the tumor EGFRvIII biomarker must prevail to improve the patient's prognosis. Here, we isolated and characterized an anti-EGFRvIII vNAR from a non-immune freshwater stingray mixed library, termed vNAR R426. The vNAR R426 and pEGFRvIII interaction was demonstrated by molecular docking and molecular dynamics, and the recognition of EGFRvIII in vitro was further confirmed by cell immunofluorescence staining. Moreover, the vNAR R426 was shown to be an effective cisplatin drug carrier in the U87-MG glioma cell line. T

SUBMITTER: Manzanares-Guzman A 

PROVIDER: S-EPMC11817625 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature